1.70
前日終値:
$1.68
開ける:
$1.72
24時間の取引高:
361.45K
Relative Volume:
0.40
時価総額:
$184.08M
収益:
$27.08M
当期純損益:
$-37.00M
株価収益率:
-3.2692
EPS:
-0.52
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
+4.29%
6か月 パフォーマンス:
-32.27%
1年 パフォーマンス:
+25.93%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
ACRS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ACRS
Aclaris Therapeutics Inc
|
1.70 | 181.91M | 27.08M | -37.00M | -18.46M | -0.52 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-10 | 再開されました | Piper Sandler | Overweight |
2025-05-28 | 開始されました | Wedbush | Outperform |
2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
2024-11-19 | アップグレード | Jefferies | Hold → Buy |
2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-10-03 | 開始されました | Evercore ISI | Outperform |
2022-12-14 | 開始されました | Stifel | Buy |
2022-12-01 | 開始されました | Goldman | Buy |
2022-10-06 | 開始されました | BTIG Research | Buy |
2021-07-23 | 再開されました | Jefferies | Buy |
2021-06-15 | 開始されました | Piper Sandler | Overweight |
2021-04-21 | 開始されました | H.C. Wainwright | Buy |
2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2019-05-06 | 開始されました | SVB Leerink | Outperform |
2018-03-28 | 再開されました | Leerink Partners | Outperform |
2018-02-09 | 開始されました | Guggenheim | Buy |
2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
2016-11-29 | 開始されました | Leerink Partners | Outperform |
2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
2016-06-10 | 開始されました | Guggenheim | Buy |
2015-11-02 | 開始されました | Citigroup | Buy |
2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
What are analysts’ price targets for Aclaris Therapeutics Inc. in the next 12 monthsHarness the power of proven investment plans - jammulinksnews.com
What are the latest earnings results for Aclaris Therapeutics Inc.Build a balanced portfolio for long-term success - jammulinksnews.com
How Resilient Is Aclaris Therapeutics Inc. Stock During Economic DownturnsLong Term Secure Gain Stocks - Newser
Published on: 2025-07-27 19:20:18 - jammulinksnews.com
How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsInsider Level Guidance - Newser
What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com
What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st
Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada
Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener
Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes By Investing.com - Investing.com UK
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - The Manila Times
Aclaris Therapeutics to Present at H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025 - Nasdaq
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
Aclaris Therapeutics Inc (ACRS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
大文字化:
|
ボリューム (24 時間):